CNS Pipeline And Medicare Coverage Will Unlock Future Opportunities

Published
21 Aug 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
US$167.87
23.2% undervalued intrinsic discount
07 Aug
US$128.89
Loading
1Y
-14.5%
7D
0.4%

Author's Valuation

US$167.9

23.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 2.75%

Shared on30 Apr 25
Fair value Increased 1.48%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 1.62%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.51%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.69%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.22%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 2.33%

AnalystConsensusTarget has decreased revenue growth from 17.3% to 14.9%, decreased profit margin from 31.0% to 25.4% and increased future PE multiple from 18.8x to 20.9x.